ClinicalTrials.gg
RecruitingNCT05934331Updated Oct 19, 2026

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

A Phase 2 interventional study of LM-302 and Toripalimab in Malignant Neoplasms of Digestive Organs, sponsored by LaNova Medicines Zhejiang Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by LaNova Medicines Zhejiang Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.
Updated Oct 19, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
632
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.

02

Conditions studied

  • Malignant Neoplasms of Digestive Organs
03

In context

Lead sponsor

LaNova Medicines Zhejiang Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Aged 18-80 years old (including boundary values) .
  3. (ECOG) performance status of0-1.
  4. ≥ 3 months.
  5. Participants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard therapy (imaging confirmation required)
  6. CLDN18.2-positive subjects.
  7. At least one .
  8. Participants must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
  9. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participants with known -positive gastric cancer/adenocarcinoma of the gastroesophageal junction
  2. Participants have participated in any other clinical trial within 28 days prior to 1st dosing of medicinal product (IMP).
  3. Participants with anti-tumor treatment within 21 days prior to 1st dosing of IMP.
  4. Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis. (for cohorts treated with combination ).
  5. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v5.0.
  6. Present peripheral sensory or motor neuropathy ≥ grade 2.
  7. Participants with uncontrolled pain.
  8. Participants with symptomatic/active central nervous system(CNS).
  9. Participants who have uncontrollable third space effusion.
  10. Participants with known to antibody therapy.
  11. Participants have treated with the same target.
  12. Participants have received Strong inhibitor/strong inducer of within 14 days prior to first dose.
  13. Use of any within 28 days prior to 1st dosing of IMP.
  14. Participants with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous for therapy.
  15. Participants on anticoagulants, such as heparin and vitamin K antagonists.
  16. Clinically uncontrollable persistent recurrent vomiting.
  17. Uncontrollable/severe gastrointestinal bleeding, ulceration or diarrhea within 28 days prior to first dose of IMP.
  18. Participants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
  19. Participants who have other cancers, other than the one treated in this trial, within 2 years prior to screening.
  20. Participants who have severe cardiovascular disease.
  21. Participants who have uncontrolled or severe illness.
  22. Participants who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or other systemic medications within 2 weeks prior to the first dosing of IMP.
  23. Participants with a known history of diseases.
  24. Participants who have a history of immunodeficiency disease.
  25. Participants with infection, active or infection.
  26. female who have positive results in pregnancy test within 7 days before the first dose or are lactating.
  27. Participants who have a known psychiatric diseases or disorders that may affect compliance with the trial.
  28. Participants who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
632 participants (estimated)

Study arms

  • Experimental
    LM-302 in combination with Toripalimab

    Drug: LM-302 · Drug: Toripalimab

  • Experimental
    LM-302 in combination with other therapies

    Drug: LM-302 · Drug: Toripalimab · Drug: Capecitabine · Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules · Drug: Nivolumab · Drug: Apatinib · Drug: Gemcitabine · Drug: Tislelizumab · Drug: Anlotinib · Drug: Benmelstobart

  • Experimental
    LM-302 monotherapy

    Drug: LM-302

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    Progression free survival according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: 112 weeks

Secondary outcomes

  1. ORR

    Objective response rate (ORR)

    Time frame: 112 weeks

  2. DOR

    Duration of response (DOR)

    Time frame: 112 weeks

  3. DCR

    Disease control rate (DCR = CR + PR + SD)

    Time frame: 112 weeks

  4. OS

    Overall survival (OS)

    Time frame: 112 weeks

  5. AEs

    Incidence of adverse events

    Time frame: 112 weeks

  6. SAEs

    Incidence of serious adverse events

    Time frame: 112 weeks

  7. Temperatures

    Temperatures

    Time frame: 112 weeks

  8. Pulse in BPM

    Beat per Minute

    Time frame: 112 weeks

  9. Blood Pressure

    Blood Pressure in mmHg

    Time frame: 112 weeks

  10. Weight

    Weight in Kg

    Time frame: 112 weeks

  11. Height

    Height in centimeter

    Time frame: 112 weeks

  12. Blood Routine examination

    Laboratory tests-Blood Routine examination

    Time frame: 112 weeks

  13. Urine Routine test

    Laboratory tests-Urine Routine test

    Time frame: 112 weeks

  14. Blood biochemistry

    Laboratory tests-Blood biochemistry

    Time frame: 112 weeks

  15. Coagulation function

    Laboratory tests- Coagulation function

    Time frame: 112 weeks

  16. LVEF

    Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Time frame: 112 weeks

  17. HR

    12-lead electrocardiogram (ECG) in HR

    Time frame: 112 weeks

  18. RR

    12-lead electrocardiogram (ECG) in RR

    Time frame: 112 weeks

  19. PR

    12-lead electrocardiogram (ECG) in PR

    Time frame: 112 weeks

  20. QRS

    12-lead electrocardiogram (ECG) in QRS

    Time frame: 112 weeks

  21. QT

    12-lead electrocardiogram (ECG) in QT

    Time frame: 112 weeks

  22. QTcF

    12-lead electrocardiogram (ECG) in QTcF

    Time frame: 112 weeks

  23. ECOG score

    Eastern Cooperative Oncology Group score

    Time frame: 112 weeks

  24. PK Parameter:Cmax

    Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Time frame: 112 weeks

  25. PK Parameter:Tmax

    PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Time frame: 112 weeks

  26. PK Parameter: AUC

    PK Parameter: Area Under the Concentration-time Curve(AUC)

    Time frame: 112 weeks

  27. PK Parameter: Cmax,ss

    PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Time frame: 112 weeks

  28. PK Parameter: Cmin,ss

    PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Time frame: 112 weeks

  29. PK Parameter: CLss

    PK Parameter: Systemic Clearance at Steady State (CLss)

    Time frame: 112 weeks

  30. PK Parameter:Rac

    PK Parameter: Accumulation Ratio (Rac)

    Time frame: 112 weeks

  31. PK Parameter: t1/2

    PK Parameter: Elimination Half-life (t1/2)

    Time frame: 112 weeks

  32. PK Parameter: Vss

    PK Parameter: Volume of Distribution at Steady-State (Vss)

    Time frame: 112 weeks

  33. PK Parameter: DF

    PK Parameter: Degree of Fluctuation (DF)

    Time frame: 112 weeks

  34. Immunogenicity of LM-302

    Anti-Drug antibody and Nab (if neccessary) will be tested.

    Time frame: 112 weeks

  35. Biomarker correlation

    For the detection of CLDN18.2 and PD-L1

    Time frame: 112 weeks

  36. AE/SAE

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 112 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2023 (actual). Primary completion is estimated for Aug 2031, 96 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Jul 2026 → Aug 2031 and completion Jul 2028 → Aug 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2023
First posted
Jul 6, 2023
StartActual
Jul 27, 2023
Primary completionEst.
Aug 6, 2031was Jul 2026
CompletionEst.
Aug 6, 2031was Jul 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 1, 2026→Aug 6, 2031
Oct 19, 2026
Study completion
Jul 1, 2028→Aug 6, 2031
Oct 19, 2026
Enrollment
276→632
Oct 19, 2026
Eligibility
4 inclusion criteria edited; 21 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedSubjectsParticipants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
  • EditedSubjectsParticipants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard first-line therapy (imaging confirmation required)
  • EditedSubjectsParticipants must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
  • EditedSubjectsParticipants who are able to communicate well with investigators and understand and adhere to the requirements of this study.
Exclusion criteria
  • EditedSubjectsParticipants with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction
  • EditedSubjectsParticipants have participated in any other clinical trial within 28 days prior to 1st dosing of investigational medicinal product (IMP).
  • EditedSubjectsParticipants with anti-tumor treatment within 21 days prior to 1st dosing of IMP.
  • EditedSubjectsParticipants with uncontrolled pain.
  • EditedSubjectsParticipants with symptomatic/active central nervous system(CNS)metastases.
  • EditedSubjectParticipants who have uncontrollable third space effusion.
  • EditedSubjectsParticipants with known hypersensitivity to antibody therapy.
  • EditedSubjectsParticipants have treated with the same target.
  • EditedSubjectsParticipants have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose.
  • EditedSubjectsParticipants with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous glucocorticoids for adjuvant therapy.
  • EditedSubjectsParticipants on anticoagulants, such as heparin and vitamin K antagonists.
  • EditedSubjectsParticipants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
  • EditedSubjectsParticipants who have other cancers, other than the one treated in this trial, within 2 years prior to screening.
  • EditedSubjectsParticipants who have severe cardiovascular disease.
  • EditedSubjectsParticipants who have uncontrolled or severe illness.
  • EditedSubjectsParticipants who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of IMP.
  • EditedSubjectsParticipants with a known history of autoimmune diseases.
  • EditedSubjectsParticipants who have a history of immunodeficiency disease.
  • EditedSubjectsParticipants with HIV infection, active HBV or HCV infection.
  • EditedSubjectParticipants who have a known psychiatric diseases or disorders that may affect compliance with the trial.
  • EditedSubjectParticipants who is judged as not eligible to participate in this study by the investigator.
Oct 19, 2026
Interventions
Added Drug: Tislelizumab·Drug: Anlotinib·Drug: Benmelstobart·Drug: LM-302. Arms added: LM-302 monotherapy
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Jul 1, 2026→Aug 6, 2031
    Study completion Jul 1, 2028→Aug 6, 2031
    Enrollment 276→632
    Eligibility 4 inclusion criteria edited; 21 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedSubjectsParticipants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
    • EditedSubjectsParticipants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard first-line therapy (imaging confirmation required)
    • EditedSubjectsParticipants must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
    • EditedSubjectsParticipants who are able to communicate well with investigators and understand and adhere to the requirements of this study.
    Exclusion criteria
    • EditedSubjectsParticipants with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction
    • EditedSubjectsParticipants have participated in any other clinical trial within 28 days prior to 1st dosing of investigational medicinal product (IMP).
    • EditedSubjectsParticipants with anti-tumor treatment within 21 days prior to 1st dosing of IMP.
    • EditedSubjectsParticipants with uncontrolled pain.
    • EditedSubjectsParticipants with symptomatic/active central nervous system(CNS)metastases.
    • EditedSubjectParticipants who have uncontrollable third space effusion.
    • EditedSubjectsParticipants with known hypersensitivity to antibody therapy.
    • EditedSubjectsParticipants have treated with the same target.
    • EditedSubjectsParticipants have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose.
    • EditedSubjectsParticipants with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous glucocorticoids for adjuvant therapy.
    • EditedSubjectsParticipants on anticoagulants, such as heparin and vitamin K antagonists.
    • EditedSubjectsParticipants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
    • EditedSubjectsParticipants who have other cancers, other than the one treated in this trial, within 2 years prior to screening.
    • EditedSubjectsParticipants who have severe cardiovascular disease.
    • EditedSubjectsParticipants who have uncontrolled or severe illness.
    • EditedSubjectsParticipants who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of IMP.
    • EditedSubjectsParticipants with a known history of autoimmune diseases.
    • EditedSubjectsParticipants who have a history of immunodeficiency disease.
    • EditedSubjectsParticipants with HIV infection, active HBV or HCV infection.
    • EditedSubjectParticipants who have a known psychiatric diseases or disorders that may affect compliance with the trial.
    • EditedSubjectParticipants who is judged as not eligible to participate in this study by the investigator.
    Interventions Added Drug: Tislelizumab·Drug: Anlotinib·Drug: Benmelstobart·Drug: LM-302. Arms added: LM-302 monotherapy
    + 4 other changes: verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05934331
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jul 27, 2023
Primary completion
Aug 6, 2031 (estimated)
Completion
Aug 6, 2031 (estimated)
Last update
Oct 19, 2026

Study contacts

Alex Yuan
Contact
AlexYuan@Lanovamed.com
021-68889618
Paul Kong
Contact
paulkong@lanovamed.com
021-68889618
Jin Li
principal investigator · Shanghai East Hospital
Jieer Ying
principal investigator · Zhejiang Cancer Hospital
Haiping Jiang
principal investigator · First Affiliated Hospital of Zhejiang University
Rushen Zhao
principal investigator · Zibo Municipal Hospital
Chunmei Bai
principal investigator · Peking Union Medical College Hospital
Yu Zheng
principal investigator · Sir Run Run Shaw Hospital
Jing Dai
principal investigator · Zhongnan Hospital
Yiping Mou
principal investigator · Zhejiang Provincial People's Hospital
Haijiao Yan
principal investigator · The First People's Hospital of Changzhou
Aiping Zhou
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Xianglin Yuan
principal investigator · Tongji Hospital
Yabin Xia
principal investigator · First Affiliated Hospital of Wannan Medical College
Mingzhu Huang
principal investigator · Fudan University
Lixin Wan
principal investigator · Nanyang Central Hospital
Jun Zhou
principal investigator · Shanghai Gaobo Cancer Hospital
Youwei Zhang
principal investigator · Xuzhou Central Hospital
Ning Wu
principal investigator · Shanghai Pudong New District Gongli Hospital
Deliang Fu
principal investigator · Huashan Hospital
Kuirong Jiang
principal investigator · The First Affiliated Hospital with Nanjing Medical University
Liang Liu
principal investigator · Zhongshan Hospital Affiliated with Fudan University
Shiwei Guo
principal investigator · Changhai Hospital
Wenhai Huang
principal investigator · Jinshan Hospital Affiliated to Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tecotabart vedotin

Start the discussion